NE NEWS SERVICE
NEW DELHI, MAR 24
Drug firm Cadila Healthcare on Wednesday said the company along with its arm Zydus Pharmaceuticals (USA) Inc has reached settlement of patent litigation with Celgene Corporation for Revlimid.
“As part of the settlement, the parties will file consent judgments with the United States District Court for the District of New Jersey that enjoin Zydus Cadila from marketing generic lenalidomide before the expiration of the patents-in-suit, except as provided for in the settlement,” Cadila Healthcare said in a regulatory filing.
“The company and its subsidiary Zydus Pharmaceuticals USA Inc have reached an agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide),” the filing said.
